Brolucizumab

Brolucizumab
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized
Target	Vascular endothelial growth factor A (VEGFA)
Clinical data
Trade names	Beovu
Other names	brolucizumab-dbll, RTH258, DLX1008
AHFS/Drugs.com	Monograph
MedlinePlus	a620001
License data	US DailyMed: Brolucizumab;
Pregnancy; category	AU: D;
Routes of; administration	Intravitreal
ATC code	S01LA06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	1531589-13-5;
PubChem CID	252827371;
IUPHAR/BPS	8713;
DrugBank	DB14864;
ChemSpider	none;
UNII	XSZ53G39H5;
KEGG	D11083;
Chemical and physical data
Formula	C1164H1768N310O372S7
Molar mass	26281.17 g·mol−1

Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).^[6]^[5]

The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision).^[6]^[5] The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye).^[6]^[5]

Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A).^[6] VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.^[6]^[5]

^ Medicine registrations Archived 28 June 2023 at the Wayback Machine Australian Government
^ "Beovu Product information". Health Canada. 25 April 2012. Archived from the original on 8 August 2024. Retrieved 29 May 2022.
^ "Summary Basis of Decision (SBD) for Beovu". Health Canada. 23 October 2014. Archived from the original on 23 June 2023. Retrieved 29 May 2022.
^ "Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 9 March 2020. Archived from the original on 24 September 2020. Retrieved 3 May 2020.
^ ^a ^b ^c ^d ^e "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.
^ ^a ^b ^c ^d ^e ^f Cite error: The named reference Beovu EPAR was invoked but never defined (see the help page).

[1] Medicine registrations Archived 28 June 2023 at the Wayback Machine Australian Government

[2] "Beovu Product information". Health Canada. 25 April 2012. Archived from the original on 8 August 2024. Retrieved 29 May 2022.

[3] "Summary Basis of Decision (SBD) for Beovu". Health Canada. 23 October 2014. Archived from the original on 23 June 2023. Retrieved 29 May 2022.

[4] "Beovu 120 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 9 March 2020. Archived from the original on 24 September 2020. Retrieved 3 May 2020.

[Beovu_FDA_label-5] "Beovu- brolucizumab injection, solution". DailyMed. 13 January 2020. Archived from the original on 9 January 2021. Retrieved 3 May 2020.

[Beovu_EPAR-6] ^ ^a ^b ^c ^d ^e ^f Cite error: The named reference Beovu EPAR was invoked but never defined (see the help page).

[1]

[2]

[3]

[4]

[5]

[6]